BLAINTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREALINJECTABLE
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
PORTRAZZA (necitumumab) by Eli Lilly and Company is her1 antagonists [moa]. Approved for non-small cell lung cancer, squamous non-small cell lung cancer. First approved in 2015.
Drug data last refreshed 18h ago
Mechanism of Action
HER1 Antagonists
Pharmacologic Class:
Epidermal Growth Factor Receptor Antagonist
Worked on PORTRAZZA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.